Repeated Muscle Vibration in Acute Stroke

Sponsor
University of Roma La Sapienza (Other)
Overall Status
Completed
CT.gov ID
NCT03697525
Collaborator
(none)
22
1
2
50
0.4

Study Details

Study Description

Brief Summary

prospective randomized double-blind sham-controlled study aimed to investigate the effects of Repeated Muscle Vibration (rMV) on motor recovery in acute stroke patients, treated within 72 hours from symptoms onset

Condition or Disease Intervention/Treatment Phase
  • Device: Vibration
N/A

Detailed Description

This is a prospective randomized double-blind sham-controlled study. After enrollment (T-0), patients are randomly placed into the vibration group (VG) or the control group (CG), by using a computer-generated randomization list. VG patients receive rMV treatment while those of CG receive the sham one. Both treatments are carried out during the 1st, 2nd and 3rd day after enrollment. Physiokinesitherapy (PT) is carried out in all patients every day, starting soon after T-0 clinical evaluation. Patients are re-evaluated after 4 ± 1 days (T-1), at the end of treatment.

Upon admission, all participants' demographic details and medical history are recorded. All patients undergo a clinical examination, performed at all time-points by an experienced investigator, blinded to group assignment and different from the recruiting one. Clinical evaluation consists of stroke severity evaluation, by means of NIH Stroke Scale; motor and functional limbs abilities are evaluated by using both the Fugl-Meyer scale and the Motricity Index; post-stroke spasticity is assessed with Ashworth scale, modified by Bohannon and Smith.

All participants undergo a daily rehabilitation program. The physical therapist is instructed about duration, frequency, and content of therapy in order to ensure uniformity in treatment procedures, and blinded to patients' treatment allocation.

Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).

The rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break.

During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle.

Otherwise, the CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients are only subject to the faint buzzing sound of the vibrator

Study Design

Study Type:
Interventional
Actual Enrollment :
22 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
prospective randomized double-blind sham-controlled studyprospective randomized double-blind sham-controlled study
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
double-blind
Primary Purpose:
Treatment
Official Title:
Effects of Repeated (Focal) Muscle Vibration (rMV) on Motor Recovery After Acute Stroke: a Randomized Sham-controlled Study
Actual Study Start Date :
Jan 1, 2016
Actual Primary Completion Date :
Jul 1, 2018
Actual Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Vibration Group (VG)

VG participants undergo rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle

Device: Vibration
Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
Other Names:
  • Repeated (focal) Muscle Vibration (rMV)
  • Sham Comparator: Control Group (CG)

    CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients were only subject to the faint buzzing sound of the vibrator. Sham rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle

    Device: Vibration
    Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
    Other Names:
  • Repeated (focal) Muscle Vibration (rMV)
  • Outcome Measures

    Primary Outcome Measures

    1. Motor Recovery [4 ± 1 days]

      Motor recovery is expressed as the differences over time (from T-0 to T-1) between the two groups concerning Motricity Index scale scores. The Motricity Index is an ordinal scale that evaluates motor skills and functional limbs in patients with neurological diseases. The movements object of the evaluation are in total 6 (3 for each limb) The scores range from 0 (i.e. no movement) to 33 (ie normal movements) for a maximum of 100 for each limb.

    Secondary Outcome Measures

    1. Motor Recovery within/associated to synergies [4 ± 1 days]

      Motor recovery occurring within/associated to synergies is expressed as the differences over time (from T-0 to T-1) between the two groups concerning Fugl-Meyer scale scores. This scale consists of 10 subtests (6 subtests for the upper limb and 4 for the lower limbs), which evaluate the movements occurring within the synergies (flexor or extensor) and the movements that occur with the association of synergies. It consists of 50 items and provides a maximum score of 100 points, which corresponds to normal traction (66 points for the upper limb, 34 for the lower one) and a minimum score of 0 (no traction)

    2. Stroke Recovery [4 ± 1 days]

      Stroke recovery is expressed as the differences over time (from T-0 to T-1) between the two groups concerning NIH Stroke Scale scores. This scale assesses the stroke severity; it consists of 11 items and the total score goes from a minimum of 0 = normal neurological examination at a maximum of 42, severe severe neurological deficit.

    3. Spasticity Recovery [4 ± 1 days]

      Post-stroke Spasticity is assessed with Ashworth scale, modified by Bohannon and Smith. The total score goes from 0 (no spasticity) to 4 (maximum spasticity grade)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age >18,

    • first ever stroke detected by Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) scan

    • ischemic or hemorrhagic stroke within 72 hours from symptom onset

    • motor deficit of the upper and/or lower limb;

    • ability to perform at least a minimal isometric voluntary contraction of the affected limb

    Exclusion Criteria:
    • TIA, or rapidly improving stroke

    • cerebral venous thrombosis

    • patients presenting with aphasia, neglect, or apraxia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Human Neurosciences, "Sapienza" University of Rome Rome Italy 00184

    Sponsors and Collaborators

    • University of Roma La Sapienza

    Investigators

    • Principal Investigator: Vittorio Di Piero, Prof, Università di Roma La Sapienza

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Vittorio Di Piero, Associate Professor, University of Roma La Sapienza
    ClinicalTrials.gov Identifier:
    NCT03697525
    Other Study ID Numbers:
    • URomLS - VDiPiero
    First Posted:
    Oct 5, 2018
    Last Update Posted:
    Mar 25, 2020
    Last Verified:
    Mar 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Vittorio Di Piero, Associate Professor, University of Roma La Sapienza
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 25, 2020